Teladoc Health Introduces AI-Powered SoloVitals and SoloScribe for Hospitals and Health Systems

Teladoc Health introduces AI features SoloVitals and SoloScribe to enhance patient care and streamline clinical workflows.

Quiver AI Summary

Teladoc Health announced the launch of two AI-powered features, SoloVitals and SoloScribe, within its Solo enterprise smart care platform for healthcare systems. SoloVitals offers contactless vital sign measurement using a patient’s camera-equipped device to analyze facial changes and provide vital metrics, while SoloScribe serves as an ambient AI documentation tool that generates structured clinical notes, allowing clinicians to focus more on patient care. Both tools aim to streamline technology use in healthcare settings by integrating essential AI functionalities into a single platform, ultimately reducing administrative burdens and enhancing patient care delivery. With the Solo technology already deployed in over 15,000 locations globally, SoloScribe is now available, and SoloVitals will have a broader release in December 2026.

Potential Positives

Teladoc Health has introduced two innovative AI-powered capabilities, SoloVitals and SoloScribe, which enhance its Solo platform, demonstrating its commitment to advancing virtual care technology.
SoloVitals' ability to capture vital signs contactlessly can improve patient care by facilitating remote consultations and reducing the need for physical interaction, especially beneficial in current healthcare landscapes.
SoloScribe streamlines clinical documentation, allowing clinicians to focus on patient care rather than paperwork, thus potentially increasing efficiency and improving the overall quality of care.
The integration of these capabilities into existing workflows simplifies technology management for health systems and positions Teladoc as an agile leader in the rapidly evolving digital health market.

Potential Negatives

Both new AI capabilities, SoloVitals and SoloScribe, are only available to select customers and are in private preview, which may indicate a lack of confidence in full-scale deployment or unresolved concerns regarding their performance.
The reliance on emerging technologies for vital sign measurement and documentation raises potential concerns regarding accuracy and reliability, which could impact patient care and hospital trust in the platform.
The terminology around "embedded" AI may downplay the complexities involved in integrating these technologies into existing systems, possibly leading to customer dissatisfaction if expectations are not met.

FAQ

What are SoloVitals and SoloScribe by Teladoc Health?

SoloVitals is an AI-powered solution for non-contact vital sign measurements, while SoloScribe aids in clinical documentation within the Solo platform.

How does SoloVitals measure vital signs?

SoloVitals utilizes a patient's existing camera-enabled device to analyze facial skin color changes for heart and respiration rate measurements.

What are the benefits of using SoloScribe?

SoloScribe helps clinicians focus on patients by automating clinical note-taking and integrating seamlessly into the virtual care workflow.

When will SoloVitals and SoloScribe be widely available?

SoloScribe is currently available, while SoloVitals will have a full release expected in December 2026.

How does Teladoc Health support healthcare providers?

Teladoc Health provides integrated AI solutions to enhance patient care, reduce administrative burdens, and streamline technology across health systems.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$TDOC Insider Trading Activity

$TDOC insiders have traded $TDOC stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.

Here’s a breakdown of recent trading of $TDOC stock by insiders over the last 6 months:

CHARLES III DIVITA (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 3 sales selling 55,011 shares for an estimated $380,071.
KELLY BLISS (President, U.S. Group Health) has made 0 purchases and 4 sales selling 15,179 shares for an estimated $126,067.
FERNANDO M. RODRIGUES (President of BetterHelp) has made 0 purchases and 2 sales selling 15,249 shares for an estimated $114,131.
ADAM C VANDERVOORT (CHIEF LEGAL OFFICER, SECRETARY) sold 7,906 shares for an estimated $60,299
CARLOS NUENO (President, International) sold 6,196 shares for an estimated $47,256
JOSEPH RONALD CATAPANO (Chief Accounting Officer) has made 0 purchases and 3 sales selling 1,592 shares for an estimated $11,811.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$TDOC Revenue

$TDOC had revenues of $606.9M in Q2 2026. This is a decrease of -3.95% from the same period in the prior year.

You can track TDOC financials on Quiver Quantitative's TDOC stock page.

You can access data on TDOC stock through the Quiver Quantitative API.

$TDOC Hedge Fund Activity

We have seen 149 institutional investors add shares of $TDOC stock to their portfolio, and 127 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

VOSS CAPITAL, LP added 3,846,679 shares (+91.6%) to their portfolio in Q2 2026, for an estimated $32,619,837
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 3,063,252 shares (+inf%) to their portfolio in Q2 2026, for an estimated $25,976,376
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 2,040,051 shares (+inf%) to their portfolio in Q2 2026, for an estimated $17,299,632
BLACKROCK, INC. added 1,609,578 shares (+11.0%) to their portfolio in Q2 2026, for an estimated $13,649,221
ACADIAN ASSET MANAGEMENT LLC added 1,484,287 shares (+509.4%) to their portfolio in Q2 2026, for an estimated $12,586,753
AMERICAN CENTURY COMPANIES INC added 1,438,120 shares (+41.6%) to their portfolio in Q2 2026, for an estimated $12,195,257
PALE FIRE CAPITAL SE removed 1,424,729 shares (-41.9%) from their portfolio in Q2 2026, for an estimated $12,081,701

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$TDOC Price Targets

Multiple analysts have issued price targets for $TDOC recently. We have seen 2 analysts offer price targets for $TDOC in the last 6 months, with a median target of $8.75.

Here are some recent targets:

Allen Lutz from B of A Securities set a target price of $10.5 on 07/07/2026
Daniel Grosslight from Citigroup set a target price of $7.0 on 05/05/2026

Full Release

NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced two new AI-powered capabilities within Solo, its enterprise smart care platform for hospitals and health systems. SoloVitals and SoloScribe are designed to help health systems bring timely patient insights into the care environment, while reducing technology fragmentation and helping care teams stay focused on patient care.

“Health systems are under intense pressure to do more, yet they are spending more time navigating a growing number of platforms, tools and vendors, each requiring different technology and processes. Teladoc Health is extending care teams with embedded, clinically-validated AI, without the added complexity,” said Joby McKenzie, General Manager, North American Health Systems at Teladoc Health.

SoloVitals is an AI-powered contactless vital sign measurement solution that can capture heart rate and respiration rate without physically touching a patient. Using a patient’s existing camera-equipped device, such as a smart phone or tablet, SoloVitals analyzes subtle facial skin color changes through remote photoplethysmography (rPPG) technology to generate measurements. This capture provides clinicians with clinically-validated vital sign measurement during remote consultations to support better care decisions.

SoloScribe is an ambient AI documentation scribe that creates structured clinical notes in Solo, helping clinicians remain focused on the patient while documentation stays embedded in the virtual care workflow. SoloScribe supports both direct-to-patient and telemedicine device-based visits and creates a templated summary that is transferred into the EHR. This helps hospitals scale AI-assisted documentation across eligible clinicians, programs and workflows through one integrated Solo experience.

Both capabilities are embedded within Teladoc Health’s Solo platform, rather than requiring multiple disconnected point solutions. This creates a more scalable approach to AI-enabled care delivery that helps extend clinical teams, surface timely patient insights, and simplify technology management.

“When we embed practical AI directly into clinical workflows through one connected platform, we are helping to provide faster access to patient information, reduce administrative burdens, and enable hospitals to scale innovation without adding new infrastructure. This allows clinicians to remain focused on their patients and not on the technology or processes surrounding a care interaction,” said Danny Sanchez, Vice President of Technology and Innovation at Teladoc Health.

Teladoc Health’s Solo technology is installed in more than 15,000 care locations globally and offers deep integrations with EHR platforms such as Epic and Oracle Health using HL7 and FHIR standards.

SoloScribe is now generally available, and SoloVitals is available to select customers in private preview, with full general release expected in December 2026. For more information about Teladoc Health’s enterprise solutions for hospitals and health systems, click here .

About Teladoc Health
Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.

Media:
Kaitlin Rogers
[email protected]
704-604-9060